BBY Best Buy Company

SCHEDULE 13D

SCHEDULE 13D

SCHEDULE 13D

SCHEDULE 13D

This Amendment No. 12 to the Schedule 13D (this “Amendment No. 12”) relates to the common stock, par value $0.10 per share (the “Shares”), issued by Best Buy Co., Inc., a Minnesota corporation (the “Company”), and hereby amends the Schedule 13D filed with the Securities and Exchange Commission on January 15, 1996 (the “Initial Schedule”), as amended and supplemented by Amendment No. 1 filed on June 7, 2012, Amendment No. 2 filed on August 6, 2012, Amendment No. 3 filed on August 16, 2012, Amendment No. 4 filed on August 20, 2012, Amendment No. 5 filed on August 20, 2012, Amendment No. 6 filed on August 27, 2012, Amendment No. 7 filed on December 14, 2012, Amendment No. 8 filed on March 1, 2013, Amendment No. 9 filed on March 25, 2013, Amendment No. 10 filed on October 23, 2013, Amendment No. 11 filed on September 30, 2015 (the “Amendments”, together with the Initial Schedule, the “Schedule 13D”) on behalf of the Reporting Persons. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D. All items or responses not described herein remain as previously reported in the Schedule 13D.

Item 2 is hereby amended and restated in its entirety with the following:

(a)       This Schedule 13D is being filed by:

Each of the foregoing is referred to herein as a “Reporting Person” and together as the “Reporting Persons.”

(b) The address of the principal office of each of the Reporting Persons but the Family Foundation is 6600 France Avenue. S., Suite 550 Minneapolis, MN 55435. The address of the principal office of the Family Foundation is 999 Vanderbilt Rd., Suite 710 Naples, FL 34108.

(c)       Mr. Schulze is the founder, former Chairman and a former Director of the Company. He also serves as the sole managing member of RMSJS, the sole general partner of Olympus B, and the Chairman of the Trustees of the Family Foundation. The principal business of each of Olympus A and Olympus B is to invest in the capital stock of the Company. The principal business of RMSJS is to serve as the general partner of Olympus A. The principal business of the Family Foundation is to provide support for education programs, food, shelter, afterschool programs, camps, and medical human service agencies in Minnesota.

(d)       During the past five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)       During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)       Mr. Schulze is a United States citizen.

Item 4 is hereby amended and supplemented to add the following:

On March 25, 2013, Mr. Schulze and the Company entered into a letter agreement (the “Letter Agreement”) pursuant to which, among other things, Mr. Schulze will continue in his role as Chairman Emeritus of the Company, with the lifetime honorary title of “Founder and Chairman Emeritus.” The Letter Agreement was subsequently extended in 2015, 2018, 2021, and 2022. The current extension runs through Fiscal Year 2024. The original Letter Agreement gave Mr. Schulze the power to nominate two directors for appointment to the Board of Directors of the Company until he reached the age of 75, but Mr. Schulze has had no special board-nominating privileges since turning 75 in January 2016. He is now a passive investor in the Company.

This amendment now accounts for three gifts of the Shares that Mr. Schulze gave to third parties. Each instance is documented in the table amending Item 5(c). These Shares were given for purely gratuitous purposes for no consideration out of Mr. Schulze’s passively-held equity stake.

Mr. Schulze has periodically and passively held Shares through several term trusts for estate planning purposes. Each term trust has since expired. Upon expiration, the Shares in each term trust were either distributed to (1) excluded irrevocable trusts, or (2) Mr. Schulze’s included revocable trust, always without exchanging consideration. Although these transactions are more completely accounted for in the table amending Item 5(c), the term trusts’ names and termination dates are as follows: (1) the Richard M. Schulze 2017 Term Trust (expired on June 12, 2019), (2) the Richard M. Schulze 2018 Term Trust (expired on December 3, 2020), (3) the 2008 Schulze Family Term Trust No. 2 (expired on December 23, 2020), and (4) the Richard M. Schulze 2020 Term Trust (expired on March 23, 2022).

The Richard M. Schulze Family Foundation periodically sells Shares on the open market to finance its charitable endeavors. The table amending Item 5(c) documents several such instances of these sales, each of which was made for this purpose. Additionally, in July 2019, Mr. Schulze made several sales of the Shares on the open market as part of his personal long-term strategy for asset diversification and liquidity. Each such documented sale was made for this purpose and for fair-market cash consideration. The table also documents several sales that were effectuated on the open market in November 2019 pursuant to a Rule 10b-5 plan established by Mr. Schulze on October 25, 2019, as disclosed in his December 2, 2019 Form 4 (the “Plan”). Mr. Schulze also received fair-market cash consideration for these shares.

Mr. Schulze’s amendment also includes three adjustments in the equivalent number of Shares held by Mr. Schulze through his Best Buy 401(k). An equivalent number of Shares held in the stock fund is calculated and included in quarterly statements by dividing its closing balance by the closing price of the Company’s common stock as reported by the New York Stock Exchange on the last trading date of the statement period. Equivalent shares are approximate, since in this Fund participants own units of a Fund that primarily invests in stock and a very small portion of cash.

Item 5 is hereby amended and restated in its entirety with the following:

The responses of the Reporting Persons to rows (7) through (13) of the cover pages of this Schedule 13D are incorporated herein by reference.

(a)       The percentages used herein are calculated based upon 221,264,454 Shares outstanding as of December 2, 2022, as set forth in the December 22, 2022 Form 10-Q.

As of the date of this Amendment No. 12, the Reporting Persons beneficially owned in the aggregate 23,068,885 Shares, constituting approximately 10.4% of the outstanding Shares. As of the date of this Amendment No. 12, the Reporting Persons may be deemed to have direct beneficial ownership of the Shares as follows:

(i)        Mr. Schulze, individually, as the account holder of the Best Buy 401(k) Retirement Savings Plan held in his name, and as trustee of the Richard M. Schulze Revocable Trust and the Richard M Schulze Qualified Terminable Interest Property Marital Trust II, beneficially owns 23,068,885 Shares, constituting approximately 10.4% of the outstanding Shares. Mr. Schulze disclaims beneficial ownership of such Shares for all other purposes. This figure excludes (a) 9,033,299 Shares held in trusts for the benefit of Mr. Schulze’s children, grandchildren, and the children of Mr. Schulze’s former spouse, and (b) 172,831 Shares in the Richard M Schulze Qualified Terminable Interest Property Marital Trust I, in each case as to which Mr. Schulze disclaims beneficial ownership.

(ii) Olympus A may be deemed to own beneficially (as that term is defined in Rule 13-d under the Securities Exchange Act of 1934) 31,672 Shares, constituting approximately 0.01% of the outstanding Shares. Olympus A disclaims beneficial ownership of such Shares for all other purposes.

(iii) Olympus B may be deemed to own beneficially (as that term is defined in Rule 13-d under the Securities Exchange Act of 1934) 950,169 Shares, constituting approximately 0.4% of the outstanding Shares. Olympus B disclaims beneficial ownership of such Shares for all other purposes.

(iv) RMSJS, as the sole general partner of Olympus A, may be deemed to own beneficially (as that term is defined in Rule 13-d under the Securities Exchange Act of 1934) 31,672 Shares, constituting approximately 0.01% of the outstanding Shares. RMSJS disclaims beneficial ownership of such Shares for all other purposes.

(v)       The Family Foundation may be deemed to own beneficially (as that term is defined in Rule 13-d under the Securities Exchange Act of 1934) 590,148 Shares, constituting approximately 0.3% of the outstanding Shares. The Family Foundation disclaims beneficial ownership of such Shares for all other purposes.

(b)        Mr. Schulze has the sole power to vote or direct the vote of and to dispose of or direct the disposition of 21,496,896 Shares. Mr. Schulze has shared power to vote or direct the vote of and to dispose of or direct the disposition 1,571,989 Shares. Olympus A may be deemed to share with Mr. Schulze the power to vote or direct the vote of and to dispose of or direct the disposition of 31,672 Shares. Olympus B may be deemed to share with Mr. Schulze the power to vote or direct the vote of and to dispose of or direct the disposition of 950,169 Shares. RMSJS may be deemed to share with Mr. Schulze the power to vote or direct the vote of and to dispose of or direct the disposition of 31,672 Shares beneficially owned by Olympus A. The Family Foundation may be deemed to share with Mr. Schulze the power to vote or direct the vote of and to dispose of or direct the disposition of 590,148 Shares.

(c) The following table sets forth all transactions in the Shares effected by Mr. Schulze during the 60 days prior to the date of this Amendment No. 12 and prior to the date of each amendment that should have been filed since the date of Amendment No. 11:

² Mr. Schulze gifted 466 shares to his grandchild on November 30, 2018. This was the only transaction made in the 60-day period prior to the material change in his beneficial ownership, which was largely attributable to a Company stock buyback resulting in an outstanding share reduction of 13,612,024 (from 282,713,593 shares as of March 29, 2018 to 269,101,569 shares as of December 5, 2018).

³ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.24, inclusive.

⁴ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.24, inclusive.

⁵ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.08, inclusive.

⁶ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.08, inclusive.

⁷ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.01, inclusive.

⁸ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.86, inclusive.

⁹ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.01, inclusive.

¹⁰ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.86, inclusive.

¹¹ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.275, inclusive.

¹² The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.275, inclusive.

¹³ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.35, inclusive.

¹⁴ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.01, inclusive.

¹⁵ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.05, inclusive.

¹⁶ This adjustment to the equity in Mr. Schulze’s 401(k) account reflects the amount of equivalent shares added to the account as of July 19, 2019, ahead of the filing of the July 22, 2019 Form 4. An equivalent number of Shares held in the stock fund is calculated and included in quarterly statements by dividing its closing balance by the closing price of the Company’s common stock as reported by the New York Stock Exchange on the last trading date of the statement period. Equivalent shares are approximate, since in this Fund participants own units of a Fund that primarily invest in stock and a very small portion of cash.

¹⁷ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.75, inclusive.

¹⁸ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.12 to $81.70, inclusive.

¹⁹ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.12 to $81.095, inclusive.

²⁰ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.195 to $82.38, inclusive.

²¹ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.12 to $82.02, inclusive.

²² The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.12 to $81.115, inclusive.

²³ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.51 to $80.15, inclusive.

²⁴ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.54 to $81.37, inclusive.

²⁵ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.58 to $80.51, inclusive.

²⁶ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.63 to $81.43, inclusive.

²⁷ This adjustment to the equity in Mr. Schulze’s 401(k) account reflects the amount of equivalent shares added to the account as of November 28, 2022, ahead of the filing of the November 30, 2022 Form 4. An equivalent number of Shares held in the stock fund is calculated and included in quarterly statements by dividing its closing balance by the closing price of the Company’s common stock as reported by the New York Stock Exchange on the last trading date of the statement period. Equivalent shares are approximate, since in this Fund participants own units of a Fund that primarily invest in stock and a very small portion of cash.

(d)       To the knowledge of the Reporting Persons, no person other than the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares that are the subject of this Schedule 13D.

(e)       Not applicable.

Item 6 is hereby amended and supplemented to add the following:

Effective October 25, 2019, Mr. Schulze adopted the Plan, a discussion of which is contained in Item 4 hereof and is incorporated into this Item 6 by reference.

²⁸ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.16 to $82.37, inclusive.

²⁹ The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.16 to $82.155, inclusive.

³⁰ This adjustment to the equity in Mr. Schulze’s 401(k) account reflects the amount of equivalent shares added to the account as of December 31, 2022, ahead of the filing of this Amendment. An equivalent number of shares held in the stock fund is calculated and included in quarterly statements by dividing its closing balance by the closing price of the Company’s common stock as reported by the New York Stock Exchange on the last trading date of the statement period. Equivalent shares are approximate, since in this Fund participants own units of a Fund that primarily invest in stock and a very small portion of cash.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATED: January 19, 2023

[Signature Page to Schedule 13D/A (Amendment No. 12)]